ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2697

A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis
Abstract Number: 2053

A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Abstract Number: 1133

A Proteomic Analysis Of Subclinical Synovial Inflammation Associated With Monosodium Urate Crystal Deposition
Abstract Number: 0037

A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Abstract Number: 0231

A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
Abstract Number: 1144

A quantitative study of renal medulla echogenicity in 250 Vietnames gout patients shows correlation with poor renal function
Abstract Number: 0692

A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
Abstract Number: 0114

A rare variant in the Extl3 gene is associated with altered Wnt signaling pathway in a novel mouse model of axial spondyloarthritis
Abstract Number: 0735

A Real-World Study from the Greater Paris Clinical Data Warehouse
Abstract Number: 1923

A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
Abstract Number: 0699

A Retrospective Comparison of Transplant Outcomes in Patients with and without Systemic Sclerosis
Abstract Number: 0698

A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
Abstract Number: 0209

A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Abstract Number: 1122

A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
Abstract Number: 2177

A Rheumatologic Ultrasound (RhUS) Educational Framework: Expert Consensus on RhUS Skills for Adult Rheumatology Fellows in the United States

« Previous Page
1
…
3
4
5
6
7
…
181
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].